Comparative Pharmacology
Head-to-head clinical analysis: AVOPEF versus TAZVERIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVOPEF versus TAZVERIK.
AVOPEF vs TAZVERIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avopef is a synthetic peptide analog that acts as a selective antagonist of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), modulating pain pathways and stress responses. It also exhibits partial agonist activity at mu-opioid receptors, contributing to its analgesic and anxiolytic effects.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
Adults: 400 mg intravenously every 8 hours for 7-14 days.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 2.0-3.5 hours; prolonged to 6-12 hours in renal impairment.
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Renal: 70-80% unchanged; Biliary/Fecal: 15-20%; minor hepatic metabolism.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Category C
Category C
Antineoplastic
Antineoplastic, EZH2 Inhibitor